Innvolution has received a production license for its Cardiac Cath Lab manufactured at the Andhra Pradesh MedTech Zone (AMTZ), marking a significant step in India’s medical technology journey. The achievement strengthens the country’s capability to design, manufacture, and supply advanced cardiovascular imaging systems under the “Make in India” initiative.
Strengthening Domestic Manufacturing
The new production facility enhances India’s ability to manufacture high-end Cath Labs locally, reducing dependence on imports while improving access to advanced cardiac care. Moreover, the expansion reinforces AMTZ’s role as a leading medical device manufacturing hub that supports innovation, quality, and large-scale production.
As reported by Medgate Today, this development reflects the growing momentum of India’s MedTech ecosystem and highlights the industry’s focus on building globally competitive healthcare technologies.
Driving Innovation and Accessibility
Innvolution continues to invest in research, advanced imaging technologies, and indigenous product development. Consequently, healthcare providers can expect reliable, high-performance Cath Lab systems designed to meet both domestic and international standards. The initiative also supports faster deployment of cardiac care infrastructure across hospitals.
Supporting the ‘Make in India’ Vision
The production license represents more than a regulatory milestone. It demonstrates India’s increasing capability to manufacture sophisticated medical devices that can compete globally. Furthermore, the collaboration between Innvolution and AMTZ showcases how innovation, manufacturing excellence, and supportive infrastructure can accelerate the country’s journey toward self-reliance in medical technology.